Peptide Guide

Peptide Cycle Chart: How Long to Run Common Peptides

How long people run 18 common peptides, how long they take off, and how much evidence actually sits behind each cycle length.

Last reviewed November 19, 2026 6 min read By Dave Belmonte, Founder
CyclingPeptide GuideChart
Back to Expert Insights

Educational only, not medical advice: Most peptides on this chart are research chemicals that are not FDA-approved. The cycle lengths below are what people commonly report or what labels and trials used, not a personal plan. This page does not cover doses; see the Peptide Dosage Guide for those. Talk to a qualified healthcare provider before starting, stopping or changing anything.

Short Answer

Most research peptides are run in cycles of a few weeks to a few months, followed by a break. Healing peptides like BPC-157 and TB-500 are commonly run 8 to 12 weeks; growth hormone peptides like CJC-1295 and Ipamorelin are often run 12 to 16 weeks with 4 to 6 weeks off. These numbers come from community practice, not clinical trials. FDA-approved drugs like semaglutide and tirzepatide are different: they are taken continuously under a prescriber, and stopping them is linked to weight regain.

Peptide Cycle Chart

The "Basis" column tells you where each cycle length comes from, so you can see how much evidence sits behind it.

PeptideTypical cycleBasis
BPC-1578 to 12 weeks on, 4 offCommunity
TB-5008 to 12 weeksCommunity
CJC-1295 (no DAC)12 to 16 weeks on, 4 to 6 offCommunity
CJC-1295 (with DAC)12 to 16 weeks on, 4 to 6 offCommunity
Ipamorelin12 to 16 weeks on, 4 to 6 offCommunity
GHK-Cu (injected)Often 8 to 12 weeksCommunity
KPV (oral)VariesCommunity
SermorelinVariesCommunity
IGF-1 LR34 to 6 weeksCommunity
MOTS-cShort coursesCommunity
SemaxShort coursesCommunity
SelankIn cyclesCommunity
EpithalonShort courses, 1 to 2 times a yearCommunity
DSIPShort-termCommunity
TesamorelinPrescriber-ledFDA label
SemaglutideOngoing, under a prescriberFDA label
TirzepatideOngoing, under a prescriberFDA label
RetatrutideContinuous in clinical trials (investigational)Trial

Community means the length comes from user and vendor protocols, not a study. FDA label means it follows an approved drug's prescribing information. Trial means it reflects how a drug was given in clinical trials.

Why People Cycle Peptides

The usual reason is the idea that receptors become less responsive with constant stimulation, so a break "resets" the response. For most peptides this has not been tested in people. The best human evidence comes from the growth hormone releasing peptides. In a study of 12 healthy older adults given hexarelin, a GH releasing peptide, by injection twice daily for 16 weeks, the growth hormone response fell significantly by week 4 and week 16, then returned to baseline 4 weeks after stopping. Hexarelin is a relative of ipamorelin, not the same molecule, so this supports the logic of breaks for GH peptides without proving any specific schedule.

Research reference: Rahim A, O'Neill PA, Shalet SM. "Growth Hormone Status during Long-Term Hexarelin Therapy." The Journal of Clinical Endocrinology & Metabolism. 1998. DOI: 10.1210/jcem.83.5.4812

Other common reasons to cycle are simpler: to see whether the benefit holds after stopping, to limit long-term exposure to compounds with little long-term safety data, and to get bloodwork without the peptide on board.

Peptides That Are Taken Continuously

GLP-1 drugs are the main exception. In the STEP 4 trial, 803 adults who had already lost weight on semaglutide for 20 weeks were randomly assigned to continue it or switch to placebo for 48 more weeks. Those who continued kept losing weight, while those switched to placebo regained weight. That is why the labels for semaglutide and tirzepatide describe ongoing treatment under a prescriber rather than on and off cycles, and why retatrutide was given continuously in its trials.

Research reference: Rubino D, Abrahamsson N, Davies M, et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial." JAMA. 2021. PMID: 33755728

Special Cases

GHK-Cu and copper

GHK-Cu is a copper peptide, so long runs add copper. The adult Tolerable Upper Intake Level for copper is 10 mg a day from all sources, set to protect the liver, and it was set for copper you eat, not inject. Long-term injected GHK-Cu has not been studied. Anyone with Wilson's disease or another copper disorder should avoid it. See GHK-Cu for more.

Source: Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Chapter 7, Copper. National Academies Press, 2001. NCBI Bookshelf

Short-course peptides

Epithalon, Semax, MOTS-c and DSIP are usually described in short courses rather than long cycles, often repeated once or twice a year. Human data on all four is limited, so the course lengths are conventions, not tested schedules.

What to Check Between Cycles

A break is a good time for bloodwork, since it shows where you are without the peptide on board. Many people repeat the same panel at baseline, near the end of a cycle and during the break. Common markers include a CMP for liver and kidney function, a CBC, fasting glucose and HbA1c, IGF-1 for growth hormone peptides, and copper markers for long GHK-Cu runs. See the Peptide Bloodwork Guide, track your results with Lab Analysis, and log each cycle with How to Track Your Peptide Cycles.

For doses, mixing and schedules, see the Peptide Dosage Guide. To build a stack around your goals, try the Protocol Builder. For more real questions, browse Peptide Questions Answered.

Frequently Asked Questions

How long should you cycle peptides?

Most research peptides are run for a few weeks to a few months, then paused. Healing peptides like BPC-157 and TB-500 are commonly run 8 to 12 weeks, and growth hormone peptides like CJC-1295 and Ipamorelin are often run 12 to 16 weeks with 4 to 6 weeks off. These lengths come from community practice, not clinical trials.

Why do people take breaks from peptides?

The main idea is that receptors may become less responsive with constant use. In a 16-week human study of hexarelin, a growth hormone releasing peptide, the growth hormone response dropped during treatment and returned to baseline 4 weeks after stopping. Breaks also allow clean bloodwork and limit long-term exposure to compounds with little safety data.

Do you need to cycle semaglutide or tirzepatide?

No. Semaglutide and tirzepatide are FDA-approved and are taken continuously under a prescriber. In the STEP 4 trial, people who stopped semaglutide regained weight while those who continued kept losing weight.

Can you take BPC-157 year round?

There is no human research on taking BPC-157 long term, so nobody knows. Community protocols commonly run it 8 to 12 weeks with about 4 weeks off. Talk to a healthcare provider before using it at all.

What bloodwork should you get between peptide cycles?

Common markers include a CMP for liver and kidney function, a CBC, fasting glucose and HbA1c, IGF-1 for growth hormone peptides, and copper markers for long GHK-Cu use. Many people check at baseline, near the end of a cycle and during the break.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. Most peptides on this page are research chemicals that are not FDA-approved, and cycle lengths are reported practice, not a personal plan. Always consult a qualified healthcare provider before starting any peptide protocol.